Molecular profile of breast cancers in Guinean oncological settings

Traoré, B.; Koulibaly, M; Diallo, Aissatou Taran; Bah, Malick

doi:10.11604/pamj.2019.33.22.18189

Cited by 18 publications

(27 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This distribution was found to be in concurrence with the results obtained from others western [12,23] and north African countries [33,34].…”

Section: Discussionsupporting

confidence: 92%

“…This age at presentation in our current study is in agreement with a previous Togolese study were the mean age at diagnosis of cancer was 50 years [10]. This is also similar to the mean age reported in Ghanaian patients at Korle bu Hospital [16] and in Indian women [17], but different from the relatively younger age of women with breast cancer reported in several studies in others countries in Africa [12,[18][19][20][21][22].…”

Section: Discussionsupporting

confidence: 92%

“…The proportion of patients expressing ER (50.4%) is superior to those of PR positive (37.6%). The same observation was reported by different authors [12,23,29,31].…”

Section: Discussionsupporting

confidence: 90%

“…In the present study, positive ER immunostaining was found in 50.4% of cases. Our result is similar to that reported by Bangaly in Guinea [12]. However, our nding is lower than those reported in western countries [5] and Asia [ 29,30].…”

Section: Discussionsupporting

confidence: 85%

“…In this retrospective study, IHC was performed in only the third (37.5%) of breast cancers diagnosed from 2016 to 2020 because of the unavaibility and the high cost of receptor testing. As in our country, access to IHC remains limited in most countries of Sub-Saharan Africa [12][13][14][15].…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Breast Cancer in Togolese Women: Immunohistochemistry Subtypes

ADANI-IFE¹,

AMEGBOR²,

DOH³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Molecular classification of breast cancer is an important factor for prognostic and clinical outcome. There are no data regarding molecular breast cancer subtypes among Togolese women. The objective of this study was to evaluate the expression of ER, PR, HER2 and molecular subtypes of breast cancer receptor in Togolese patients and to establish the correlation between clinical and histological data and molecular types. Methods Clinicopathologic data of patients were collected from clinical records. Immunohistochemistry biomarkers (ER, PR and HER2) were assessed in patients who have been diagnosed with invasive breast cancer from March 2016 to March 2020 in the department of oncology. The analysis of variance and the Chi-square Test were used to analyze the data. Results A total of 117 cases were collected. Mean age of patients was 52.05 ± 12.38 with an age range of 30 to 85 years. Half of patients were over 50 years old and majority (70.9%) was postmenopausal. More than half of patients (52.1%) presented with T3-T4tumors.The most common histologic subtype of breast cancer was invasive ductal carcinoma of no special type (95.7%). Tumors grade 2 were predominant (51.3%) followed by grade 3 (42.7%). Advanced carcinomas were found in 69 patients (59%). The percentage of ER+, PR + and HER2 positive tumors was 50.4%, 37.6% and 15.4% respectively. The predominant molecular subtype was Luminal A (42.7%) followed by Triple negative (41.9%), Luminal B subtype (9.4%) and HER2 enriched (6%). There was significant association between tumor size and breast cancer subtypes (p = 0.026) but no correlation was found with age, stage, menopausal status and histologic grade. Conclusion Breast carcinoma in our patients are high grade tumors and are diagnosed at advanced stage. Luminal A and triple negative are the two predominant breast cancer subtypes in Togolese women. Consequently, Receptor testing availability should be a priority in order to offer the best breast cancer treatment.

show abstract

“…This distribution was found to be in concurrence with the results obtained from others western [12,23] and north African countries [33,34].…”

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 92%

“…The proportion of patients expressing ER (50.4%) is superior to those of PR positive (37.6%). The same observation was reported by different authors [12,23,29,31].…”

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 85%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Breast Cancer in Togolese Women: Immunohistochemistry Subtypes

ADANI-IFE¹,

AMEGBOR²,

DOH³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

Prevalence of Histological Characteristics of Breast Cancer in Rwanda in Relation to Age and Tumor Stages

et al. 2020

View full text Add to dashboard Cite

Breast cancer is a complex disease, and it is the most common cause of morbidity and mortality among women worldwide. In Sub-Saharan Africa, the clinical characteristics and tumor profiles of breast cancer are still unknown. In the present study we aimed to determine breast tumor profiles of the Rwandan patients in relation to age and tumor stages. We compare our findings to related results from other sub-Saharan Africa studies. Data on age at diagnosis, tumor stage, and hormonal profiles of 138 patients diagnosed between January 2015 and December 2018 were retrospectively retrieved from electronic medical records at three referral hospitals in Rwanda. We compared our results to related findings reported in other Sub-Saharan African countries. All statistical analyses were done using SPSS Inc., Chicago, IL, USA, version 20 and R software languages. The mean age at diagnosis was 49.7 years (SD = 13) and ranged from 17 to 86 years. The majority of patients (57.2%) were diagnosed before 50 years of age compared with 42.8% aged > 50 years. Tumor stage III was the commonest accounting for 62% followed by stage II with 24.8%. The distribution of breast tumor subtypes was ER−

show abstract

Are dietary factors involved in the association of CDH4 methylation and breast cancer risk?

Zhang

Long

et al. 2021

Br J Nutr

View full text Add to dashboard Cite

DNA methylation is one of the most important epigenetic modifications in breast cancer (BC) development, and long-term dietary habits have been shown to alter DNA methylation. Cadherin-4 (CDH4, a member of the cadherin family) encodes Ca2+-dependent cell-cell adhesion glycoproteins. We conducted a case-control study (380 newly-diagnosed breast cancers and 439 cancer-free controls) to explore the relationship of CDH4 methylation in peripheral blood leukocyte DNA (PBL), as well as its combined and interactive effects with dietary factors and lifestyle on BC risk. A case-only study (335 newly-diagnosed breast cancers) was conducted to analyze the association between CDH4 methylation in breast tissue DNA and dietary factors. CDH4 methylation were detected using quantitative methylation specific PCR (qMSP). Unconditional logistic regressions were used to analyze the association of CDH4 methylation in PBL DNA and BC risk. Cross-over analysis and unconditional logistic regression were used to calculate the combined and interactive effects between CDH4 methylation in PBL DNA and dietary factors in BC. CDH4 hypermethylation was significantly associated with increased BC risk in PBL DNA (ORadjusted (ORadj)= 2.70, 95% confidence interval (CI)= 1.90-3.83, P<0.001). CDH4 hypermethylation also showed significant combined effects with the consumption of <500 g/week vegetables (ORadj=4.33, 95% CI=2.63-7.10), ≤3 times/week allium vegetables (ORadj=7.00, 95% CI=4.17-11.77), <3 times/week fish (ORadj=7.92, 95% CI=3.79-16.53), <3 times/week milk (ORadj=6.30, 95% CI=3.41-11.66), >3 times/week overnight food (ORadj=4.63, 95% CI=2.69-7.99), ≥250 g/week pork (ORadj=5.59, 95% CI=2.94-10.62), and <1 time/month physical activity (ORadj=4.72, 95% CI=2.87-7.76). Moreover, consuming milk ≥ 1 times/month was significantly related with decreased risk of CDH4 methylation (OR=0.61, 95% CI=0.38-0.99) in breast tissue. Our findings may provide direct guidance on the dietary intake for specific methylated carriers to decrease their risk for developing BC.

show abstract

Molecular profile of breast cancers in Guinean oncological settings

Cited by 18 publications

References 25 publications

Breast Cancer in Togolese Women: Immunohistochemistry Subtypes

Breast Cancer in Togolese Women: Immunohistochemistry Subtypes

Prevalence of Histological Characteristics of Breast Cancer in Rwanda in Relation to Age and Tumor Stages

Are dietary factors involved in the association of CDH4 methylation and breast cancer risk?

Contact Info

Product

Resources

About